A team of scientists at the University of British Columbia's TRIUMF facility are celebrating a major triumph after signing a deal to produce a rare cancer drug which previously relied on nuclear waste.
The rare drug, a radioisotope known as actinium-225, started making headlines about five years ago when four treatments of it were administered to a German man who was just weeks from death and suffering from multiple cancerous tumours. Eight months later, the tumours had disappeared.
The lab has figured out how to produce actinium-225 at their facility without using nuclear waste, which could mean the ability to produce thousands of doses of the drug. Jordan Armstrong explains how it could make a major difference.
For more info, please go to
Subscribe to Global News Channel HERE:
Like Global News on Facebook HERE:
Follow Global News on Twitter HERE:
Follow Global News on Instagram HERE: